FDA Finalizes Guidance on Co-Crystals in NDAs and ANDAs Post author:Sam Post published:February 14, 2018 Post category:Drug Industry Daily The FDA finalized new guidance establishing co-crystals as a drug product intermediate. Source: Drug Industry Daily You Might Also Like Fourteen Companies Land FDA Warnings for False Cancer Claims April 25, 2017 Joint AdComm Signals Unanimous Support for OTC Naloxone Nasal Spray February 14, 2023 FDA Grants Accelerated Approval to First Drug to Decrease Urine Protein Caused by Rare Kidney Disease December 16, 2021
FDA Grants Accelerated Approval to First Drug to Decrease Urine Protein Caused by Rare Kidney Disease December 16, 2021